Literature DB >> 17452481

In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents.

Nikolaos G Almyroudis1, Deanna A Sutton, Annette W Fothergill, Michael G Rinaldi, Shimon Kusne.   

Abstract

We evaluated the in vitro susceptibilities of 217 zygomycetes to amphotericin B, ketoconazole, fluconazole, itraconazole, voriconazole, posaconazole, caspofungin, and flucytosine. The significant in vitro activity of posaconazole against several species appears to support its reported clinical efficacy. Decreased susceptibility to amphotericin B was noted with Cunninghamella bertholletiae.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17452481      PMCID： PMC1913247          DOI： 10.1128/AAC.00452-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  Comparison of three commercial assays and a modified disk diffusion assay with two broth microdilution reference assays for testing zygomycetes, Aspergillus spp., Candida spp., and Cryptococcus neoformans with posaconazole and amphotericin B.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2006-08-30       Impact factor: 5.948

2.  In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes.

Authors:  Qiu N Sun; Annette W Fothergill; Dora I McCarthy; Michael G Rinaldi; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

3.  Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.

Authors:  Eric Dannaoui; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.

Authors:  Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

Review 5.  Zygomycetes in human disease.

Authors:  J A Ribes; C L Vanover-Sams; D J Baker
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

6.  In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.

Authors:  S Arikan; M Lozano-Chiu; V Paetznick; J H Rex
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

7.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

8.  In vitro susceptibilities of zygomycetes to conventional and new antifungals.

Authors:  Eric Dannaoui; Joseph Meletiadis; Johan W Mouton; Jacques F G M Meis; Paul E Verweij
Journal:  J Antimicrob Chemother       Date:  2003-01       Impact factor: 5.790

9.  In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model.

Authors:  Qiu N Sun; Laura K Najvar; Rosie Bocanegra; David Loebenberg; John R Graybill
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

10.  Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi.

Authors:  D J Diekema; S A Messer; R J Hollis; R N Jones; M A Pfaller
Journal:  J Clin Microbiol       Date:  2003-08       Impact factor: 5.948
View more
  61 in total

1.  Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales.

Authors:  Roxana G Vitale; G Sybren de Hoog; Patrick Schwarz; Eric Dannaoui; Shuwen Deng; Marie Machouart; Kerstin Voigt; Wendy W J van de Sande; Somayeh Dolatabadi; Jacques F Meis; Grit Walther
Journal:  J Clin Microbiol       Date:  2011-11-09       Impact factor: 5.948

2.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

3.  Evidence implicating Thamnostylum lucknowense as an etiological agent of rhino-orbital mucormycosis.

Authors:  Immaculata Xess; Sarita Mohapatra; M R Shivaprakash; Arunaloke Chakrabarti; Gerald L Benny; Kerry O'Donnell; Arvind A Padhye
Journal:  J Clin Microbiol       Date:  2012-02-01       Impact factor: 5.948

4.  Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries.

Authors:  Livio Pagano; Oliver A Cornely; Alessandro Busca; Morena Caira; Simone Cesaro; Cristiana Gasbarrino; Corrado Girmenia; Werner J Heinz; Raoul Herbrecht; Cornelia Lass-Flörl; Annamaria Nosari; Leonardo Potenza; Zdenek Racil; Volker Rickerts; Donald C Sheppard; Arne Simon; Andrew J Ullmann; Caterina Giovanna Valentini; Jörg Janne Vehreschild; Anna Candoni; Maria J G T Vehreschild
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

5.  Activity of posaconazole and other antifungal agents against Mucorales strains identified by sequencing of internal transcribed spacers.

Authors:  Ana Alastruey-Izquierdo; Maria Victoria Castelli; Isabel Cuesta; Araceli Monzon; Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

6.  Mucor circinelloides as a cause of invasive maxillofacial zygomycosis: an emerging dimorphic pathogen with reduced susceptibility to posaconazole.

Authors:  Zia U Khan; Suhail Ahmad; Arnost Brazda; Rachel Chandy
Journal:  J Clin Microbiol       Date:  2009-01-26       Impact factor: 5.948

Review 7.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

8.  Posaconazole enhances the activity of amphotericin B against hyphae of zygomycetes in vitro.

Authors:  Susanne Perkhofer; Maria Locher; Manuel Cuenca-Estrella; Reinhard Rüchel; Reinhard Würzner; Manfred P Dierich; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

9.  Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

Authors:  Russell E Lewis; Ronen Ben-Ami; Leyla Best; Nathaniel Albert; Thomas J Walsh; Dimitrios P Kontoyiannis
Journal:  J Infect Dis       Date:  2012-12-13       Impact factor: 5.226

10.  Identification of fungal pathogens in a patient with acute myelogenic leukemia using a pathogen detection array technology.

Authors:  Sagarika Banerjee; Kristen N Peck; Michael D Feldman; Mindy G Schuster; James C Alwine; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2016-04-02       Impact factor: 4.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.